This review presents research published over the last year examining use of urate-lowering therapy (ULT) as well as trends over time in adherence to this class of agents. Additionally, it explores factors associated with nonadherence to ULTs for chronic gout and interventions to improve chronic gout management.
INTRODUCTION
Gout is the most common inflammatory arthritis, affecting 8.3 million (4%) Americans [1] and costing the US$27.4 million annually for the management of incident cases [2] . The pathogenesis of gout has been well elucidated, with the causative agent being monosodium urate crystals. Chronic elevation of uric acid levels above saturation results in the formation of crystals that preferentially deposit around peripheral joints [3] . Untreated hyperuricemia can evolve into gout with symptomatic episodes associated with joint, bursal, or soft tissue inflammation and potential long-term consequences, including irreversible joint damage and deformity. The rise in the number of gout cases over the last few decades has been attributed to aging population, increased use of diuretics, and low-dose aspirin, and increased prevalence of diseases, including hypertension, renal disease, obesity, and metabolic syndrome [4] . Despite a clear understanding of the mechanism of gout and the factors associated with the condition, gout is poorly controlled in many patients resulting in joint and soft tissue pain, reduced quality of life, and inability to perform usual activities including working [5] [6] [7] [8] [9] . Additionally, there is some evidence to suggest that patients with active gout are at greater risk for cardiovascular disease, stroke, and chronic kidney disease [10, 11] .
Optimal gout management requires active engagement with patients as partners given the need for lifestyle modification. Patient education is critical for patients to incorporate lifestyle changes such as weight loss in those with a BMI over 25 and limitation of specific foods including beef, pork, and seafood, which are known risk factors for gout flares. Patients with gout should also be advised to limit alcohol intake given that episodic intake of alcohol of all types, even moderate amounts, is associated with an increased risk of recurrent attacks [12, 13] . Conversely, patients should be encouraged to consume low-fat or nonfat dairy products which may reduce gout flares [11] .
Medication management of acute and chronic gout requires that patients receive medications when needed and that they are adherent to the prescribed treatment regimens. For acute gouty flares, use of nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or oral corticosteroids is recommended [14] . For patients with a diagnosis of gouty arthritis and frequent attacks, chronic kidney disease stage 2 or greater, one or more tophi, or past urolithiasis, chronic urate-lowering therapy (ULT) is required [11] to lower the serum uric acid (sUA) level below the saturation point with the goal of 5 or 6 mg/dl (the lower target is recommended for patients with tophaceous deposits) [15] . These include xanthine oxidase inhibitors (e.g. allopurinol and febuxostat), which inhibit conversion of hypoxanthine to xanthine, and of xanthine to uric acid [16] . Other available ULTs are uricosuric drugs (e.g. probenecid, sulfinpyrazone, and benzbromarone), which increase the excretion of uric acid in the urine. Pegloticase is a recombinant uricase that catalyzes the oxidation of uric acid to allantoin, which is water soluble and readily excreted. Because of the risk of mobilization flares when initiating a ULT, prophylaxis with colchicine or an NSAID is recommended [14] .
Adhering to these treatment regimens is often challenging for gout patients. Patients can be confused regarding the different treatment approaches with 'as needed' dosing for acute gout and long-term therapy for chronic gout [17] . Additionally, patients may not see the value in ULT if they have a flare upon initiation and are not educated on the goals of chronic therapy. This scenario occurs commonly as physicians infrequently report the use of prophylaxis at the time of ULT initiation [18, 19] . As outlined in Fig. 1 , this review explores new research within the past year that investigates trends in ULT adherence and the factors associated with nonadherence including race and ethnicity, as well as an evaluation of the facilitators of, and barriers to optimal gout management. Lastly, we will summarize recently published clinical interventions to improve gout care.
ADHERENCE TO MEDICATIONS FOR GOUT
Two studies over the last year have examined gout management and overall nonadherence to medications. Kuo et al. [20 & ] used the Clinical Practice Research Datalink and investigated the pattern of gout management from 1997 to 2012 in the United Kingdom. Specifically, they found that the proportion of patients treated with a ULT had not changed over the previous 15-year time interval and by 2012 only 37.6% [95% confidence interval (CI) 37.3-39] of prevalent gout patients received a ULT. Similarly, in 2012 among incident gout patients, 18.6% (95% CI 17.6-19.6) were treated with a ULT within 6 months of diagnosis; this proportion increased to 27.3% (95% CI 26.1-28.5) by 12 months. Both of these rates changed only marginally over the study period. The author also examined adherence to ULTs, which was assessed using the proportion of days covered, which calculates the proportion of days a participant has a prescription for each specified interval. In contrast to the lack of change in the proportion of patients treated with a ULT, patients who received treatments showed improved adherence over the study period. Specifically, in 1997, 28.3% of patients were adherent, defined as a proportion of days covered of at least 80%, which increased to 39.7% (95% CI 39.1-40.2) in 2012.
On the other side of the globe, Horsburgh et al. Young age and race/ethnicity is an important risk factor for ULT nonadherence.
Chronic gout patients who have low adherence rates report lack of education regarding the role ULTs in overall disease management and copayment costs are barriers to regular medication usage.
Patient-centered interventions that included education on pharmacotherapy and lifestyle modifications with individualized medication titration based on regular laboratory testing resulted in the majority of participants achieving the target serum urate acid level.
Optimizing gout care Nasser-Ghodsi and Harrold be 3%. Of note, the authors were unable to limit the sample to those with a diagnosis of gout. However, the utilization of allopurinol is much less than the estimated 5% prevalence of gout in New Zealand [22] . Adherence to allopurinol was evaluated using the medication possession ratio, which is defined as the supply of medication dispensed during a followup year divided by the number of days in the year (364) with a ratio more than 0.8 typically considered acceptable adherence [23] . Overall, 88% of the population was considered adherent, which is substantially higher than previous studies which have reported the proportion of adherent patients to be between 10 and 46% [24] . This is likely influenced by the approach used by the researchers in the calculation that included only participants who received greater than a 90-day supply of allopurinol, thus, excluding patients with lower adherence rates. Factors associated with adherence were explored with lower adherence rates in younger versus older age groups and those of Maori ethnicity versus non-Maori. These results confirmed previous studies that have identified younger age as a significant risk factor for nonadherence [25] .
FURTHER INVESTIGATION INTO THE FACILITATORS OF AND BARRIERS TO OPTIMAL GOUT CARE
Taking medications is a complex behavior that requires patients to fill prescriptions for prescribed medication as well as understanding how to take the medications and how the medication fits into disease management. Furthermore, patients need to have the financial resources to pay for the medications and well as the motivation and self-management skills to take the medication regularly. A recent study [26 & ] evaluated facilitators of and barriers to ULT adherence in African American patients stratified by low and high ULT adherence. Patients with high ULT adherence reported prevention of gout flares and pain as main motivators for persisting on therapy. Additionally, patients reported that ULT intake allowed them to eat foods they liked in moderation without having flare-ups with encouraged medication adherence. Lastly, incorporating ULT intake as part of their daily routine was a successful strategy to encourage adherence. Barriers to optimal gout care reported in the low adherence group included the belief that ULTs were not effective. Patients reported confusion as to whether the ULT was specific for acute flares versus chronic prophylaxis of flares. Many patients were also concerned about prescription copayment costs, potential side-effects of the medication, and concerns about taking multiple medications on a daily basis [26 & ].
These findings confirm what others have previously described suggesting there are deficits in patient self-management skills and patient education. In prior studies [18, 27] are unclear of the role of allopurinol (prevention versus pain relief), what triggers a gout flare, and are unhappy with the information provided by health professionals [18, 27] . Clearly there are many factors that impede medication adherence. Patients have knowledge deficits in how ULTs work and their effectiveness, as well as lack of financial resources to pay for the medications. Providers need to be aware of these concerns in order to develop strategies to tailor their care to the specific needs of individual gout patients including patient education and self-management training.
INTERVENTIONS TO IMPROVE GOUT MANAGEMENT
To address the challenges in providing optimal management, a pharmacist-based gout management programme was employed in a large integrated health plan in the United States [28 && ]. This pilot study enrolled patients with chronic or recent gout referred by their primary care physicians for the purpose of ULT management. The authors reported on 100 consecutive patients. The programme was designed to be a telephone-delivered intervention providing educational and dietary guideline materials. The study pharmacist employed a protocol to titrate gout medication dosing to a target sUA level of 6 mg/dl or lower based on laboratory testing. Of the 100 participants referred to the clinic, 95 started (five declined to participate) of whom 13 did not complete the programmes (nonadherence was the reason for the majority of patients who dropped out). Of note, 78 completed the programme and successfully achieved two consecutive sUA measurements less than 6 mg/dl. This pilot study is encouraging, suggesting adherence can be improved with a pharmacist-staffed programme. However, it still remains to be seen how much impact these types of clinics will have on the larger gout population given the preliminary nature of the study and the enrolled patients were a select group in that they agreed to participate. This is similar to the approach utilized by Rees et al. [29] in the United Kingdom. The study enrolled 106 eligible participants reporting ongoing attacks of gout. Participants were initially evaluated by a rheumatologist during an approximately 1 h appointment, which involved a clinical examination, detailed education on gout, and development of individualized plans for addressing modifiable risk factors for gout and treatment with a ULT. The remaining intervention was delivered by a specialist nurse either on the phone or in person to monitor clinical progress and success of lifestyle modification as well as titration of ULT dosages based on sUA levels and address any concerns or challenges faced by patients. Follow-up frequency was determined by individual needs. Of the 106 participants, 96% achieved the therapeutic target (sUA <6 mg/dl) at study end (85% with sUA <5 mg/dl).
CONCLUSION
In summary, gout is the most common inflammatory arthritis and is associated with substantial pain, reduced quality of life, and inability to perform daily activities. Despite a good understanding of its pathogenesis and effective strategies to 'cure' the condition, numerous studies have shown that the management of gout is not optimal for most patients. New research published over the last year confirms that many patients with gout in the United Kingdom and New Zealand are not receiving ULTs. Among those who have been prescribed these agents, adherence to ULTs remains low, although it has improved in the United Kingdom over the last 15 years. Factors associated with nonadherence have been identified in New Zealand and the United States to be related to race/ethnicity, patient age, and lack of understanding regarding the role of ULTs and their benefits, as well as associated patient copayment costs. Finally, a pharmacist-delivered protocol-based intervention to improve gout management was shown to lower sUA levels in a high percentage of patients with recurrent gout in an integrated healthcare system. Given the burden of gout on the population and its associated impact on patients, more investigation is needed into novel approaches to address barriers to optimal medication management to a target sUA level as well as incorporation of lifestyle changes.
